Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Kang-Li Wang,Ming Tao,Tian-Jiao Wei,Rui Wei
DOI: https://doi.org/10.4252/wjsc.v13.i1.64
2021-01-01
World Journal of Stem Cells
Abstract:Diabetes, one of the most common chronic diseases in the modern world, has pancreatic beta cell deficiency as a major part of its pathophysiological mechanism. Pancreatic regeneration is a potential therapeutic strategy for the recovery of beta cell loss. However, endocrine islets have limited regenerative capacity, especially in adult humans. Almost all hypoglycemic drugs can protect beta cells by inhibiting beta cell apoptosis and dedifferentiation via correction of hyperglycemia and amelioration of the consequent inflammation and oxidative stress. Several agents, including glucagon-like peptide-1 and gamma-aminobutyric acid, have been shown to promote beta cell proliferation, which is considered the main source of the regenerated beta cells in adult rodents, but with less clarity in humans. Pancreatic progenitor cells might exist and be activated under particular circumstances. Artemisinins and gamma-aminobutyric acid can induce alpha-to-beta cell conversion, although some disputes exist. Intestinal endocrine progenitors can transdeterminate into insulin-producing cells in the gut after FoxO1 deletion, and pharmacological research into FoxO1 inhibition is ongoing. Other cells, including pancreatic acinar cells, can transdifferentiate into beta cells, and clinical and preclinical strategies are currently underway. In this review, we summarize the clinical and preclinical agents used in different approaches for beta cell regeneration and make some suggestions regarding future perspectives for clinical application.
What problem does this paper attempt to address?